PEGylated exenatide injection (PB-119) improves beta-cell function and insulin resistance in treatment-naïve type 2 diabetes mellitus patients.

Liu, Xu; Song, Ling; Zhang, Yuanhui; Li, Haiyan; Cui, Cheng; Liu, Dongyang

Liu, Xu; Song, Ling; Zhang, Yuanhui; Li, Haiyan; Cui, Cheng; Liu, Dongyang.

Liu X; Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
Song L; Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing, China.
Zhang Y; Center of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
Li H; Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
Cui C; Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing, China.
Liu D; Center of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.

Front Pharmacol ; 14: 1088670, 2023.

Article en En | MEDLINE | ID: mdl-37781697

Palabras clave

PB-119; beta-cell function; insulin resistance; oral minimal model; type 2 diabetes

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Año: 2023 Tipo del documento: Article